ABSTRACT
Mujer de 31 años con antecedentes de obesidad mórbida a, cirugía bariátrica, desnutrición severa crónica, laparotomía exploratoria por abdomen agudo séptico y trastorno hidroelectrolítico. Presento en su post quirúrgico (3er día) en la unidad de cuidados intensivos, Mielinolisis póntica central. Un hallazgo inusual en este caso, fue la ausencia de hiponatremia y/o su corrección brusca, quien comúnmente se asocia a esta enfermedad y a su pronóstico. Analizando todas sus comorbilidades y factores de riesgo, pensamos que existe evidencia que justifique su enfermedad. Según las fuentes revisadas (PubMed), es el primer caso reportado en América Latina. (AU)
A 31-year-old woman, with a history of morbid obesity, bariatric surgery, chronic severe malnutrition, exploratory laparotomy for acute abdomen and septic electrolyte disorder. In his post-surgical (Third day) at intensive care unit, presented central pontine myelinolysis. An unusual finding in this case was the absence of hyponatremia and I or its sharp correction, which is commonly associated with this disease and its prognosis. Analyzing all comorbidities and risk factors, we suspect, that there is evidence to support your disease. According to the sources reviewed (PubMed), is the first case reported in Latin America. (AU)
Subject(s)
Humans , Female , Adult , Rehabilitation , Myelinolysis, Central Pontine , Coma , HyponatremiaABSTRACT
Positron emission tomography (PET) with fluorine-18-2-d-deoxyglucose (FDG) currently is being integrated into clinical oncology because it provides unique functional information that can be applied to the management of cancer. In particular, it is useful for assessing tumor activity and growth, evaluating efficacy of therapy, and detecting tumor recurrence. Studies have demonstrated the value of whole-body PET-FDG imaging when staging and managing abdominal malignancy.
Subject(s)
Abdominal Neoplasms/diagnostic imaging , Tomography, Emission-Computed , Tomography, Emission-Computed/instrumentation , Colonic Neoplasms/diagnostic imaging , Deoxyglucose/analogs & derivatives , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Staging , Rectal Neoplasms/diagnostic imaging , Tomography, Emission-Computed/methodsABSTRACT
In 15 patients we hypothesized the origin of epilepsies to be 'extratemporal' based on videotaped seizures and surface EEG. Neuropsychological tests and neuroimaging (CAT, MRI, and PET scans) were then compared to the hypothesized ictal sites. Neuropsychological tests were abnormal in 86.6% and FDG-PET scans were abnormal in 73%. The neuropsychological tests and PET localized or lateralized areas of dysfunction to the same sites as electroclinical characteristics did in 85% of patients (P less than 0.01, Fisher exact test). No statistically significant correlation between lesion sites on CT and MRI and the ictal origin was observed due to the high proportion of normal or non-specific scans. These observations should be verified in a larger series of extratemporal seizures.
Subject(s)
Brain/physiopathology , Epilepsies, Partial/physiopathology , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Adolescent , Adult , Brain/diagnostic imaging , Brain/pathology , Child , Child, Preschool , Epilepsies, Partial/diagnosis , HumansABSTRACT
Twenty-two patients whose electroclinical ictal characteristics suggested frontal lobe seizure foci were studied. Computed tomography (CT) scans showed abnormalities in only 32% of patients whereas magnetic resonance imaging was informative in 45%. 18FDG-Positron emission tomography (PET) scanning revealed decreased metabolism in 64% of the group. The areas of hypometabolism were focal, regional, or hemispheric. Focal frontal hypometabolism was significantly correlated with the electroclinical (semiologic) ictal localization. Therefore, FDG-PET scanning is a sensitive and specific technique for investigating patients with seizures of probable frontal lobe origins.
Subject(s)
Epilepsies, Partial/diagnosis , Frontal Lobe , Magnetic Resonance Imaging , Tomography, Emission-Computed , Tomography, X-Ray Computed , Deoxyglucose/analogs & derivatives , Electroencephalography , Epilepsies, Partial/diagnostic imaging , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Frontal Lobe/diagnostic imaging , Frontal Lobe/pathology , Humans , Television , Temporal Lobe/pathologyABSTRACT
Four 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepines were prepared and evaluated as central nervous system agents. All were active psychotropic agents as determined by animal screening tests. The most interesting compound, 11-(1-piperazinyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine, showed dual activity as an antidepressant against tetrabenazine depression and as a neuroleptic as measured by protection vs. amphetamine lethality in grouped mice.
